- Home
- FUSE vs RNXT Comparison
FUSE vs RNXT Comparison
Compare FUSE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUSE | RNXT |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 37.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FUSE | RNXT |
|---|---|---|
| Price | $1.73 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | ★ 10.9M | 204.6K |
| Earning Date | 06-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,949,000.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.87 | N/A |
| 52 Week Low | $1.45 | $0.70 |
| 52 Week High | $25.00 | $1.45 |
Technical Indicators
Market Signals| Indicator | FUSE | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 49.98 |
| Support Level | $1.65 | $0.92 |
| Resistance Level | $2.13 | $1.08 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 6.84 | 52.38 |
Price Performance
Historical ComparisonAbout FUSE Fusemachines Inc.
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.